BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
-9.09%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$17.4B
AUM Growth
+$17.4B
(-15%)
Cap. Flow
+$303M
Cap. Flow
% of AUM
1.74%
Top 10 Holdings %
Top 10 Hldgs %
85.01%
Holding
123
New
2
Increased
15
Reduced
4
Closed
3
Top Buys
| 1 |
Incyte
INCY
|
$201M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$31.5M |
| 3 |
TSVT
2seventy bio
TSVT
|
$21M |
| 4 |
Replimune Group
REPL
|
$17.3M |
| 5 |
Travere Therapeutics
TVTX
|
$16.3M |
Top Sells
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$17.9M |
| 2 |
Legend Biotech
LEGN
|
$17.4M |
| 3 |
OPT
Opthea Limited American Depositary Shares
OPT
|
$3.43M |
| 4 |
ALBO
Albireo Pharma, Inc. Common Stock
ALBO
|
$2.43M |
| 5 |
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
|
$1.55M |
Sector Composition
| 1 | Healthcare | 98.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Krystal Biotech
KRYS
$4.35B
| $53.7M | 0.31% |
807,735
| – | – |
|
27
Insmed
INSM
$30.3B
| $50.7M | 0.29% |
2,156,001
| – | – |
|
28
Pacific Biosciences
PACB
$378M
| $49.5M | 0.28% |
5,444,963
| – | – |
|
29
Rhythm Pharmaceuticals
RYTM
$6.75B
| $47.5M | 0.27% |
4,125,062
+261,823
| +7% | +$3.02M |
|
30
Heron Therapeutics
HRTX
$204M
| $46.5M | 0.27% |
8,131,678
| – | – |
|
31
Entrada Therapeutics
TRDA
$202M
| $44.2M | 0.25% |
4,704,419
| – | – |
|
32
Instil Bio
TIL
$196M
| $41.9M | 0.24% |
3,893,700
| – | – |
|
33
Alkermes
ALKS
$4.95B
| $39.5M | 0.23% |
1,500,000
| – | – |
|
|
KDNY
34
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $38.2M | 0.22% |
2,334,102
| – | – |
|
35
Verastem
VSTM
$585M
| $38.1M | 0.22% |
26,988,898
+5,497,268
| +26% | +$7.75M |
|
|
JBIO
36
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $37.9M | 0.22% |
2,070,010
+238,221
| +13% | +$4.37M |
|
37
Immatics
IMTX
$662M
| $35.3M | 0.2% |
4,423,731
| – | – |
|
|
TSVT
38
DELISTED
2seventy bio
TSVT
| $35.2M | 0.2% |
2,062,744
+1,229,508
| +148% | +$21M |
|
39
Nurix Therapeutics
NRIX
$723M
| $34.4M | 0.2% |
2,454,082
| – | – |
|
|
VERV
40
DELISTED
Verve Therapeutics
VERV
| $32.3M | 0.19% |
1,416,530
| – | – |
|
41
Ultragenyx Pharmaceutical
RARE
$3.04B
| $32.3M | 0.19% |
444,444
| – | – |
|
42
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $27.8M | 0.16% |
2,799,577
| – | – |
|
|
43
Replimune Group
REPL
$460M
| $27.4M | 0.16% |
1,611,703
+1,018,308
| +172% | +$17.3M |
|
44
Axsome Therapeutics
AXSM
$6.09B
| $25.3M | 0.15% |
610,970
| – | – |
|
|
DBVT
45
DBV Technologies
DBVT
$249M
| $23.2M | 0.13% |
14,614,264
| – | – |
|
46
Design Therapeutics
DSGN
$339M
| $23.2M | 0.13% |
1,436,636
| – | – |
|
|
CCXI
47
DELISTED
ChemoCentryx, Inc.
CCXI
| $23M | 0.13% |
916,862
-714,404
| -44% | -$17.9M |
|
48
Xenon Pharmaceuticals
XENE
$2.99B
| $23M | 0.13% |
751,639
| – | – |
|
|
AFMD
49
DELISTED
Affimed
AFMD
| $22.5M | 0.13% |
5,153,169
+2,500,000
| +94% | +$10.9M |
|
|
ADAP
50
Adaptimmune Therapeutics
ADAP
$13.9M
| $20.3M | 0.12% |
9,830,877
| – | – |
|